YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level.
PI3K/Akt pathway
PTEN
YB-1
cold-shock proteins
proteasome
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
29 09 2021
29 09 2021
Historique:
received:
21
08
2021
revised:
24
09
2021
accepted:
28
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
9
2
2022
Statut:
epublish
Résumé
YB-1 is a multifunctional protein overexpressed in many types of cancer. It is a crucial oncoprotein that regulates cancer cell progression and proliferation. Ubiquitously expressed in human cells, YB-1 protein functions are strictly dependent on its subcellular localization. In the cytoplasm, where YB-1 is primarily localized, it regulates mRNA translation and stability. However, in response to stress stimuli and activation of PI3K and RSK signaling, YB-1 moves to the nucleus acting as a prosurvival factor. YB-1 is reported to regulate many cellular signaling pathways in different types of malignancies. Furthermore, several observations also suggest that YB-1 is a sensor of oxidative stress and DNA damage. Here we show that YB-1 reduces PTEN intracellular levels thus leading to PI3K/Akt pathway activation. Remarkably, PTEN reduction mediated by YB-1 overexpression can be observed in human immortalized keratinocytes and HEK293T cells and cannot be reversed by proteasome inhibition. Real-time PCR data indicate that YB-1 silencing up-regulates the PTEN mRNA level. Collectively, these observations indicate that YB-1 negatively controls PTEN at the transcript level and its overexpression could confer survival and proliferative advantage to PTEN proficient cancer cells.
Identifiants
pubmed: 34680946
pii: genes12101551
doi: 10.3390/genes12101551
pmc: PMC8535809
pii:
doi:
Substances chimiques
Y-Box-Binding Protein 1
0
YBX1 protein, human
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
PTEN Phosphohydrolase
EC 3.1.3.67
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Breast Cancer. 2008;15(1):73-8
pubmed: 18224398
Mol Cancer Ther. 2004 Nov;3(11):1485-92
pubmed: 15542787
Cells. 2019 Dec 31;9(1):
pubmed: 31906126
Mol Cell Biol. 2003 Sep;23(17):6139-49
pubmed: 12917336
Biochemistry (Mosc). 2011 Dec;76(13):1402-33
pubmed: 22339596
Cancer Sci. 2019 May;110(5):1536-1543
pubmed: 30903644
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546901
Front Oncol. 2015 Feb 16;5:24
pubmed: 25763354
Mol Cell Biol. 2006 Jan;26(1):277-92
pubmed: 16354698
J Thorac Oncol. 2009 Sep;4(9):1066-74
pubmed: 19648825
Genes (Basel). 2018 Oct 22;9(10):
pubmed: 30360431
Cancer Res. 2007 Oct 1;67(19):8980-4
pubmed: 17908997
Oncogene. 2010 Jan 21;29(3):403-10
pubmed: 19838214
Int J Oncol. 2015 Oct;47(4):1189-202
pubmed: 26315971
Trends Pharmacol Sci. 2011 Mar;32(3):131-40
pubmed: 21236500
J Biol Chem. 1998 May 29;273(22):13375-8
pubmed: 9593664
Cancer Lett. 2012 Jun 28;319(2):125-129
pubmed: 22266095
Nat Med. 2014 Apr;20(4):360-7
pubmed: 24633304
Nat Genet. 2010 May;42(5):454-8
pubmed: 20400965
Oncotarget. 2018 Apr 10;9(27):19039-19049
pubmed: 29721182
PLoS One. 2013 Nov 18;8(11):e80171
pubmed: 24260353
Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562
pubmed: 29858604
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):567-580
pubmed: 32931865
Cell Commun Signal. 2018 Sep 26;16(1):63
pubmed: 30257675
Cancers (Basel). 2020 Jan 29;12(2):
pubmed: 32013098
Sci Rep. 2017 May 17;7(1):2056
pubmed: 28515422